Author

D. Y. Kim

h-index 37 View on Semantic Scholar

We have 3 of 104 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.

INTRODUCTION After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV. METHODS This retrospective, m...

Min-Ji Lee, Su-Bin Lim, J. Shim et al. · Hepatology International · 0 citations

Review Open access Sep 2026

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

The role of liver biopsy in hepatocellular carcinoma (HCC) is being re-evaluated in the era of precision oncology and biomarker-driven systemic therapy. Although histopathological examination remains the diagnostic gold standard, HCC is unique among solid tumors in that accurate non-invasive imaging criteria allow diag...

Hae Lim Lee, Su-Jong Yu, Sung-Hak Lee et al. · Journal of Liver Cancer · 0 citations

Open access Jul 2026

The risk of cardiovascular events in metabolic dysfunction–associated steatotic liver disease according to fibrosis stage and diabetes status: A cohort study

Background: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality in metabolic dysfunction–associated steatotic liver disease (MASLD). We investigated whether fibrosis severity assessed using guideline-recommended noninvasive liver fibrosis pathways was associated with incident ASCV...

Jaehong Jeong, J. Hong, Dong Yun Kim et al. · Hepatology Communications · 0 citations